Maxalt Rapitab (Rizatriptan Benzoate)

Rizatriptan acts as an agonist at serotonin 5‑HT1B and 5‑HT1D receptors. This triggers constriction of dilated cranial blood vessels and blocks the release of inflammatory neuropeptides, interrupting the migraine cascade and reducing pain and associated symptoms.

The specific dose of Maxalt Rapitab is determined by the prescribing clinician based on the patient’s medical history, severity of migraine, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of rizatriptan in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit outweighs any possible risk, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Rizatriptan belongs to the triptan class, which is generally more effective for moderate to severe migraine than simple analgesics. Compared with other triptans, rizatriptan has a rapid onset of action and a similar safety profile, but individual response can vary, so clinicians choose based on patient history and tolerability.

Store Maxalt Rapitab tablets at room temperature, below 25 °C (77 °F). Keep them in the original blister pack or container, protect from moisture and direct sunlight, and keep out of reach of children.

Maxalt Rapitab is taken orally, usually as a single tablet at the first sign of a migraine attack. It should be swallowed whole with water and not be crushed or chewed. If needed, a second dose may be taken after at least two hours, following the prescriber’s guidance.

Serious risks include serotonin syndrome when combined with other serotonergic drugs, severe cardiovascular events such as myocardial infarction in patients with underlying heart disease, and rare allergic reactions that can be life‑threatening. Patients should seek immediate medical attention if they experience chest pain, severe dizziness, or signs of an allergic reaction.

Maxalt Rapitab should be avoided in patients with uncontrolled coronary artery disease, recent myocardial infarction, history of stroke or transient ischemic attack, severe hypertension, or those taking MAO inhibitors within the past 14 days. It is also contraindicated in individuals with known hypersensitivity to rizatriptan or any component of the tablet.